Articles
  

Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience

Abstract

Neuromyelitis optica is an inflammatory demyelinating disease (IDD) of the CNS, which mainly affects optic nerve and spinal cord. Autoantibodies against aquaporin-4 also known as NMO-IgG have been implicated in the pathogenesis of NMO. We evaluated the sensitivity and specificity of NMO-IgG assay for diagnosing NMO patients and differentiating them from MS patients and those with undifferentiated IDD with overlap symptoms.Eligibility of patients with demyelinating disorders was evaluated based on physical examination, laboratory and imaging studies. Thirty four definite NMO patients (disregarding NMO-IgG status), 34 multiple sclerosis (MS) patients with a history of optic neuritis (ON) or myelitis that were matched for age and disease activity and 44 patients with ON or myelitis attacks fulfilling neither criteria of MS or NMO (NMO spectrum) were selected as undifferentiated group. NMO-IgG was measured in the serum of the included patients by cell-based indirect immunofluorescence assay (IFA). NMO antibody was positive in 11 (32.3%), and 4 (9.09%) patients in NMO and undifferentiated groups, but was undetctable in MS patients. NMO antibody was 32% (95%Cl: 19-49%) sensitive in detecting NMO patients. Its specificity in differentiating NMO from MS subjects was 100 % (95% Cl: 90-!00%). NMO antibody was 95% (95% Cl: 0.88-0.98) specific in differentiating NMOs from other demyelinating diseases. Our results showed that although NMO antibody is highly specific for NMO, current method of measuring it with cell-based IFA is not highly sensitive for diagnosing NMO patients.

1. Mirshafiey A, Kianiaslani M. Autoantigens and autoantibodies in multiple sclerosis. Iran J Allergy Asthma Immunol 2013; 12(4):292-303.
2. Nandhagopal R, Al-Asmi A, Gujjar Ar. Neuromyelitis optica: an overview. Postgrad Med J 2010; 86(1013):153-9.
3. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63(3):390-6.
4. O'Riordan JI, Gallagher HL, Thompson AJ, et al.Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60(4):382-7.
5. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53(5):1107-14.
6. De Seze J, Stojkovic T, Ferriby D, Gauvrit JY, Montagne C, Mounier-Vehier F, et al. Devic's neuromylitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002; 197(1-2):57-61.
7. Poser CM and Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg 2004; 106(3):159-71.
8. Sospedra M, Martin R. Immunology of multiple sclerosis.Annu Rev Immunol 2005; 23:683-747.
9. Lalive PH. Autoantibodies in inflammatory demyelinating diseases of the central nervous system. Swiss Med Wkly 2008; 138(47-48):692-707.
10. Aghamollaii V, Harirchian MH, Modabbernia A, Ghaffarpour M, Mousavi M, Tafakhori A. Symathetic skin response(SSR) in multiple sclerosis and clinically isolated syndrome: a case-control study. Neurophysiol Clin 2011; 41(4):161-71.

11. Harirchian MH, Tekieh AH, Modabbernia A, Aghamollaii V, Tafakhori A, Ghaffarpour M, et al. Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case control study. Eur J Neurol 2012; 19(2):241-7.
12. Benarroch EE. Aquaporin-4, homeostasis, and neurologic disease. Neurology 2007; 69(24):2266-8.
13. Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008;4(4):202-14.
14. Wingerchuk DM1, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66(10):1485-9.
15. Krupp LB, Banwell B, Tenembaum S; International Pediatric MS Study Group. consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68(16 Suppl 2):S7-12.
16. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68(13):1076-7.
17. Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, et al. cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optic and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010; 7:52.
18. Lennon VA1, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody markder of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364(9541):2106-12.
19. Siritho S, Nakashima I, Takahashi T, Fujihara K, Prayoonwiwat N. AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems. Neurology 2011; 77(9):827-34.
20. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14(9):1157-74.
21. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17(8):1019-32.
22. Polman CH, Reingold SC, Banwell B, Hintzen RQ, Illes Z, Montalban X, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2):292-302.
23. Etemadifar, M., Mollabashi, M., Chitsaz, A, Behnamfar O, Bahrami E, Minagar A, et al. Seroprevalence of NMO- IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis. Clin Neurol Neurosurg 2012; 114(1):17-20.
24. Cabrea-Gomez JA, Bonnan M, Gonzalez-Quevedo A, Saiz-Hinarejos A, Marignier R, Olindo S, et al. Neuromyelitis optical positive antibodies confer a worse course in relapsing-neurmyelitis optica in Cuba and French West Indies. Mult Scler 2009; 15(7):828-33.
25. Misu T, Fujihara K and Itoyama Y. [Neuromyelitis optica and anti-aquaporin 4 antibody—an overview]. Brain Nerve 2008; 60(5):527-37.
26. Pisani, Sparaneo A, Tortorella C, Ruggieri M, Trojano M, Mola MG, et al. Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. PLoS One 2013; 8(11):e79185.
27. Klawiter EC, Alvarez E, Xu J, Paciorkowski AR, Zhu L, Parks BJ, et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 2009;72(12):1101-3.
28. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009;66(9):1134-8.
29. De Vidi I. Boursier G, Delouche N, Portalès P, Cadars E, Bouthier M, et al. Strategy for anti-aquaporin-4-antibody identification and quantification using a new cell-based assay. Clin Immunol 2011; 138(3):239-46.
30. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65(7):913-9.
31. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008; 15(3):99-105.
32. Argyriou AA, Mrakis N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 118(4):209-17.
33. Misu T, Takahashi T, Nakashima I, Fujihara K and Itoyama Y. [Neuromyelitis optica and antiaquaporin 4 antibody-distinct from multiple sclerosis]. Rinsho Byori 2009; 57(3):262-70.
34. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007;4(4):e133.
35. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131(Pt11):3072-80.

Files
IssueVol 14, No 1 (2015) QRcode
SectionArticles
Keywords
Demyelinating disorders Devic disease Multiple sclerosis Neuromyelitis optica
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Harirchian MH, Tafakhori A, Taslimi S, Aghamollaii V, Shahsiah R, Gholipour T, Mohammadi F, Zare-Shahabadi A. Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience. Iran J Allergy Asthma Immunol. 1;14(1):98-104.